For the first time, MannKind Corporation will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA(TM). To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in viewing the live webcast via the Internet may do so by visiting the Company’s website at https://www.mannkindcorp.com.
Afresa is an ultra rapid acting inhaled insulin product that has completed Phase 3 trials. The pharmacokinetic profile of Afresa sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive Afresa particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.